# A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct05668858/  
OnCo record `nct05668858` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 1/2 interventional study registered as NCT05668858 by Sichuan Baili Pharmaceutical Co., Ltd., with 70 participants enrolled, started 2023-02-10 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B001 and SI-B003.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05668858
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Study of SI-B001+SI-B003 Dual-drug No-combination or Combined Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT05668858: https://clinicaltrials.gov/study/NCT05668858

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [SI-B001](https://onco.cc/drugs/si-b001/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05668858.json